Description
| Product Name: | Recombinant Human CCL18/PARC Protein (Trx Tag) |
| SKU: | RPES8114 |
| Size: | 20μg |
| Tag: | N-Trx |
| Reactivity: | Human |
| Expression Host: | E.coli |
| Accession: | P55774 |
| Sequence: | Ala21-Ala89 |
| Calculated Molecular Weight: | 27.4 kDa |
| Observed Molecular Weight: | 30 kDa |
| Synonyms: | CKb, TSC, DCCK, DC-CK, Eotaxin, AMAC-1, CCL26, CKb7, DC-CK1, Eotaxin-3, IMAC, MIP-4, MIP-4a, SCYA26, TSC-1, AMAC1, MIP4, PARC, SCYA18, CCL18, AMAC-1, CKb7, DCCK1, DC-CK1, MIP-4, Alternative macrophage activation associated CC chemokine 1, Alternative macrophage activation-associated CC chemokine 1, CC chemokine PARC, C-C Motif Chemokine 18, CCL18(4-69), Dendritic cell chemokine 1, Macrophage inflammatory protein 4, Pulmonary and activation regulated chemokine, Pulmonary and activation-regulated chemokine, Small inducible cytokine A18, Small-inducible cytokine A18 |
| Endotoxin: | < 10 EU/mg of the protein as determined by the LAL method |
| Purity: | > 90% as determined by reducing SDS-PAGE. |
CCL18/PARC is a chemotactic cytokine involved in the pathogenesis and progression of various disorders, including cancer. Proof showed high levels of CCL18/PARC in the serum of epithelial ovarian carcinoma patients sμggesting its potential as a circulating biomarker. CCL18/PARC chemokine has an important role in chemokine-mediated tumor metastasis, and may serve as a potential predictor for poor survival outcomes for ovarian cancer. (CCL18/PARC) is predominantly secreted by M2-tumor associated macrophages (TAMs) and promotes malignant behaviors of various human cancer types. CCL18/PARC has a correlation with cardiac function in patients with AAMI and it might be considered as an indicator of poor LVEF in patients with AAMI. Circulating and WAT-secreted CCL18/PARC correlates with insulin resistance and metabolic risk score. Because CCL18/PARC is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of WAT inflammation. Macrophages are thoμght to be the main source of CCL18/PARC, and the effect of pirfenidone, an anti-fibrotic agent for idiopathic pulmonary fibrosis, on the expression of CCL18/PARC in macrophages warrants investigation.
| Bio-activity: | Not validated for activity |
| Formulation: | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
| Reconstitution: | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
| Storage: | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping: | This product is provided as lyophilized powder which is shipped with ice packs. |
